Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Holding CUE?
Track your performance easily
CUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.54 - $3.25
Previous Close$0.55
Volume124.37K
Average Volume (3M)439.70K
Market Cap
$27.48M
Enterprise Value$8.17M
Total Cash (Recent Filing)$30.03M
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 12, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding48,643,316
10 Day Avg. Volume182,521
30 Day Avg. Volume439,700
Standard Deviation0.22
R-Squared0.22
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.26
Price to Sales (P/S)3.34
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.49
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$3.75Price Target Upside563.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cue Biopharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCUE-101 in combination with pembrolizumab has demonstrated a 47% objective response rate, significantly higher than pembrolizumab alone.
Financial StabilityThe company maintains a strong cash position, providing financial stability for ongoing research and development.
Innovative TherapiesThe unveiling of the CUE-500 series represents an innovative approach to B-cell depletion that may offer advantages over existing therapies.
Bears Say
Financial PerformanceCue Biopharma's collaboration revenue for the quarter was lower than analyst estimates.
Market CompetitionThe r/m HNSCC landscape is changing fast, with Merus’s petosemtamab achieving a 67% ORR in 1L r/m HNSCC regardless of HPV16 status.
UncertaintyThe unknown details regarding the patient’s subsequent therapies introduce too many confounding factors.
---
Ownership Overview
6.03%
Insiders
7.86% Mutual Funds
19.26% Other Institutional Investors
66.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma Inc’s price range in the past 12 months?
Cue Biopharma Inc lowest stock price was $0.54 and its highest was $3.25 in the past 12 months.
What is Cue Biopharma Inc’s market cap?
Currently, no data Available
When is Cue Biopharma Inc’s upcoming earnings report date?
Cue Biopharma Inc’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Cue Biopharma Inc’s earnings last quarter?
Cue Biopharma Inc released its earnings results on Aug 19, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.08.
Is Cue Biopharma Inc overvalued?
According to Wall Street analysts Cue Biopharma Inc’s price is currently Undervalued.
Does Cue Biopharma Inc pay dividends?
Cue Biopharma Inc does not currently pay dividends.
What is Cue Biopharma Inc’s EPS estimate?
Cue Biopharma Inc’s EPS estimate is -$0.18.
How many shares outstanding does Cue Biopharma Inc have?
Cue Biopharma Inc has 48,643,314 shares outstanding.
What happened to Cue Biopharma Inc’s price movement after its last earnings report?
Cue Biopharma Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 13.158%.
Which hedge fund is a major shareholder of Cue Biopharma Inc?
Among the largest hedge funds holding Cue Biopharma Inc’s share is Slate Path Capital LP. It holds Cue Biopharma Inc’s shares valued at 3M.
---
Cue Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (563.72% Upside)
$3.75 (563.72% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 20.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.95%
12-Months-Change
Fundamentals
Return on Equity
-138.87%
Trailing 12-Months
Asset Growth
-42.14%
Trailing 12-Months
Company Description
Cue Biopharma Inc
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
---
CUE Earnings Call
Q2 2024
0:00 / 0:00
---
CUE Stock 12 Month Forecast
Average Price Target
$3.75
▲(563.72% Upside)
Technical Analysis
Best Analysts Covering CUE
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-37.54%
assigned a buy rating last month
Copying Stephen Willey's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -37.54% per trade.
---